Why people use Cerebrolysin for Alzheimer's support
Parent showing memory loss. Cerebrolysin worth pursuing? The honest answer: yes, there is real clinical evidence here, not just gym-bro consensus. Multiple RCTs (Alvarez et al., 2011) showed cognitive improvement on standardized scales (ADAS-cog) in mild-to-moderate Alzheimer's.
This page covers what's known, what's not, and what the editorial take is for normal humans considering Cerebrolysin for Alzheimer's support.
What the evidence says
Evidence tier: Strong clinical. Multiple human studies support the dosing protocol; not yet FDA-labeled for this exact indication but close.
- Multiple RCTs (Alvarez et al., 2011) showed cognitive improvement on standardized scales (ADAS-cog) in mild-to-moderate Alzheimer's.
- Effect size is modest but consistent - similar to the FDA-approved cholinesterase inhibitors.
- Sourcing in the US is the hard part - it is not FDA-approved and most US prescribers do not write for it.
Protocol notes
10-30mL IV infusion daily for 4 weeks, repeated every 3-6 months. Neurologist coordination essential.
Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.
What to skip
- Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
- Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
- Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.
Where to go next
- Full Cerebrolysin directory entry - status, sourcing, studies, what to skip
- What are peptides - if you skipped the foundation
- How peptides actually work - mechanism in plain English
- The Tier List - which ones to take seriously
- Subscribe to the dispatch